Immune checkpoint inhibitors are improving outcomes in triple-negative breast cancer (TNBC), but it remains crucial to take a patient-centered approach to care. Take part in this dynamic program designed to provide an individualized experience based on your current knowledge of recent and emerging evidence regarding the use of immunotherapy in the neoadjuvant and adjuvant settings. Gain expert insights and immediate feedback through customized education that is tailored to deepen your understanding and clinical skills.

Take away these lessons with a curated downloadable resource highlighting the latest evidence, guideline-aligned treatment, and emerging considerations for the use and timing of immunotherapy in early-stage TNBC.

• Evaluate the latest guidelines and clinical data on the safety and efficacy of neoadjuvant and adjuvant treatment with immunotherapy in triple-negative breast cancer (TNBC)
• Design individualized treatment strategies for patients with TNBC based on patient factors and current evidence and guidelines related to immunotherapy in the neoadjuvant and adjuvant settings

PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 0.5 contact hour (which includes 0.5 hour of pharmacology).

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

• William J Gradishar, MD (Contributing Author)
  
  Advisory Board or Panel – AstraZeneca, Genentech, Lilly, Roche-Genentech
  Consultant – Stemline
  The relationships reported above are related to the following therapeutic area: Hematology-Oncology

The following individuals have no relevant financial relationships with ineligible companies to disclose:

• Donna M Chiefari, BSc (Pharm), PharmD, RPh, FASHP (Reviewer)
• Ricardo Correa, MD, EdD, FACP, FACE, FAPCR, FACMQ (Planner)
• Lisa Wakefield, MSN, APRN, FNP-BC (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.